Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ovarian Platform Saruparib Master Protocol
2024-519044-32-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2 trial of saruparib in Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability of saruparib-based regimens. Started Jul 2025; status: completed.
02
Drugs
saruparib
03
Conditions
Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-519044-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519044-32-00.